Pharmacokinetics and safety of dolutegravir in term neonates exposed to HIV-1 (IMPAACT 2023): a phase 1, open-label, multicentre study

The Lancet HIV · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles